Equities

Arecor Therapeutics PLC

AREC:LSE

Arecor Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)131.00
  • Today's Change0.00 / 0.00%
  • Shares traded5.78k
  • 1 Year change-48.63%
  • Beta--
Data delayed at least 20 minutes, as of May 17 2024 15:44 BST.
More ▼

Profile data is unavailable for this security.

About the company

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

  • Revenue in GBP (TTM)3.38m
  • Net income in GBP-9.42m
  • Incorporated2021
  • Employees51.00
  • Location
    Arecor Therapeutics PLCChesterford Research ParkLittle ChesterfordSAFFRON WALDEN CB10 1XLUnited KingdomGBR
  • Phone+44 12 2342 6060
  • Websitehttps://arecor.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Hemogenyx Pharmaceuticals PLC0.00-6.69m20.33m17.0020.33m17.00
Skinbiotherapeutics PLC161.65k-2.88m20.34m11.0020.34m11.00
Oxford Biodynamics PLC510.00k-10.83m24.29m45.0024.29m45.00
CRUSHMETRIC Group Ltd393.37k-868.50k29.96m20.0029.96m20.00
Science in Sport PLC65.93m-7.07m31.44m158.0031.44m158.00
Sareum Holdings Plc0.00-4.26m36.70m5.0036.70m5.00
Arecor Therapeutics PLC3.38m-9.42m40.12m51.0040.12m51.00
Venture Life Group PLC51.41m921.00k51.23m165.0051.23m165.00
Data as of May 17 2024. Currency figures normalised to Arecor Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

12.44%Per cent of shares held by top holders
HolderShares% Held
Chelverton Asset Management Ltd.as of 30 Jun 20231.43m4.65%
Unicorn Asset Management Ltd.as of 30 Apr 20241.20m3.91%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2023631.69k2.06%
CRUX Asset Management Ltd.as of 30 Sep 2023554.90k1.81%
More ▼
Data from 30 Sep 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.